To compare the outcome of topical minoxidil 5% spray versus oral minoxidil 2.5 mg tablet for the treatment of androgenetic alopecia in males and females. Outcomes include efficacy of the treatment, measured by reduction in hair shedding, improvement in hair density and new hair growth as assessed by physican and patient assessment as well as safety, defined as incidence and severity of adverse events over a treatment period of 6 months
Patients with androgenic alopecia Norwood-Hamilton class 2-6 in males and Sinclair class 2-5 in females
History of androgentic alopecia for at least 1 year
18 to 50 years of age
Willing to provide informed consent
History of cardiovascular disease
Use of some other hair restoration therapy in the past 6 months such as minoxidil, finasteride or PRP
Presence of other causes of alopecia (e.g., alopecia areata, scarring alopecia).
Pregnant and lactating females